Complications of Uncontrolled Disease and Management of Comorbidities

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).